John L. Marshall
About
In The Last Decade
John L. Marshall
416 papers receiving 15.7k citations
Hit Papers
Peers
Comparison fields: 5 of 181
- Oncology 7.6k
- Surgery 4.9k
- Molecular Biology 3.6k
- Pulmonary and Respiratory Medicine 2.8k
- Cancer Research 1.9k
Countries citing papers authored by John L. Marshall
This map shows the geographic impact of John L. Marshall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John L. Marshall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John L. Marshall more than expected).
Fields of papers citing papers by John L. Marshall
This network shows the impact of papers produced by John L. Marshall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John L. Marshall. The network helps show where John L. Marshall may publish in the future.
Co-authorship network of co-authors of John L. Marshall
This figure shows the co-authorship network connecting the top 25 collaborators of John L. Marshall. A scholar is included among the top collaborators of John L. Marshall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John L. Marshall. John L. Marshall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Title | Journal | Authors | Indexed citations |
|---|---|---|---|---|
| 1 | Phase II trial of BXCL701 and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (EXPEL-PANC): Preliminary findings. | Journal of Clinical Oncology | Benjamin A. Weinberg, Allison A. Fitzgerald et al. | 2 |
| 2 | Clinical and molecular characterization of AXL in colorectal cancer: CALGB (Alliance)/SWOG 80405 and real-world data. | Journal of Clinical Oncology | Joshua Millstein, Joanne Xiu et al. | 1 |
| 3 | Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers | Nature Cancer | Magdalena Espinoza, Andrew Elliott et al. | 11 |
| 4 | Phase II study of neoadjuvant durvalumab and tremelimumab in combination with gemcitabine and cisplatin in patients with intrahepatic cholangiocarcinoma that is borderline resectable or resectable with high risk for recurrence. | Journal of Clinical Oncology | Benjamin A. Weinberg, Marcus Smith Noel et al. | 0 |
| 5 | Molecular Characterization of Appendiceal Goblet Cell Carcinoid | Molecular Cancer Therapeutics | Hiroyuki Arai, Yasmine Baca et al. | 18 |
| 6 | Clinical Validation of a Machine-learning–derived Signature Predictive of Outcomes from First-line Oxaliplatin-based Chemotherapy in Advanced Colorectal Cancer | Clinical Cancer Research | Jim Abraham, Daniel Magee et al. | 35 |
| 7 | A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer | Clinical Cancer Research | Michael J. Pishvaian, Hongkun Wang et al. | 32 |
| 8 | Comprehensive tumor profiling reveals unique molecular differences between peritoneal metastases and primary colorectal adenocarcinoma | Journal of Surgical Oncology | Matthew K. Stein, Joanne Xiu et al. | 18 |
| 9 | Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer | Clinical Cancer Research | Ryuma Tokunaga, Joanne Xiu et al. | 62 |
| 10 | A Pilot Trial of Molecularly Tailored Therapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma | SHILAP Revista de lepidopterología | Anteneh Tesfaye, Hongkun Wang et al. | 4 |
| 11 | The current state of molecular testing in the treatment of patients with solid tumors, 2019 | CA A Cancer Journal for Clinicians | Wafik S. El‐Deiry, Richard M. Goldberg et al. | 187 |
| 12 | Microsatellite instability status determined by next‐generation sequencing and compared with | Cancer Medicine | Ari M. Vanderwalde, David Spetzler et al. | 333 |
| 13 | Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers | Molecular Cancer Research | Mohamed E. Salem, Alberto Puccini et al. | 159 |
| 14 | Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma | Clinical Cancer Research | Jimmy J. Hwang, John Kuruvilla et al. | 80 |
| 15 | Mannose 6-phosphate reduces haze following excimer laser photorefractive keratectomy | UCL Discovery (University College London) | Gerard Sutton, John L. Marshall et al. | 5 |
| 16 | A HISTOPATHOLOGICAL STUDY OF SURGICAL HUMAN SPECIMEN OF TISSUE RESPONSIBLE FOR HAZE AND REGRESSION AFTER EXCIMER-LASER PHOTOREFRACTIVE KERATECTOMY | UCL Discovery (University College London) | CP Lohmann, David O’Brart et al. | 7 |
| 17 | THE EFFECT OF COLLAGENASE INHIBITORS ON CORNEAL TRANSPARENCY AFTER EXCIMER-LASER PHOTOREFRACTIVE KERATECTOMY (PRK) | UCL Discovery (University College London) | Melanie C. Corbett, John L. Marshall et al. | 1 |
| 18 | Experimental Investigation of Optical Breakdown Thresholds in Ocular Media under Single Pulse Irradiation with Different Pulse Durations | UCL Discovery (University College London) | Franco Docchio, C. A. Sacchi et al. | 50 |
| 19 | Strokes—What Is Wanted of Radiology? | Journal of the Royal College of Physicians of London | B. E. Kendall, John L. Marshall | 1 |
| 20 | Clinical and Radiologic Survey of Canine Panosteitis | Journal of the American Veterinary Medical Association | Peter F. Suter, John L. Marshall et al. | 18 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.